

# MANAGEMENT OF MODERATE PERIODONTITIS USING TEA TREE OIL GEL. A RANDOMIZED CONTROLLED CLINICAL TRIAL

**Dania M. Abdel Aziz Mohamed<sup>1\*</sup> BDS, Maha A. Abou Khadr<sup>2</sup> PhD, Sabah A. Mahmoud<sup>3</sup> PhD, Maha R. Taalab<sup>4</sup> PhD, Riham M. El Moslemany<sup>5</sup> PhD**

## ABSTRACT

**INTRODUCTION:** Conventional periodontal therapy is an effective line of treatment for moderate periodontitis patients. Act of adjunctive use of other biomaterials assist in increasing the success of this therapy. One of these adjunctive treatments is the use of tea tree oil (TTO) as a locally delivered agent.

**OBJECTIVE:** The present work aims to assess clinically the effect of intra pocket application of TTO gel in patients with moderate periodontitis.

**MATERIALS AND METHODS:** this randomized controlled clinical trial was performed on a total number of thirty pockets in thirty patients with moderate periodontitis. They were classified into a control group which comprised fifteen patients treated with scaling and root planing SRP only and a test group which comprised fifteen patients treated with SRP and locally delivered TTO gel. The clinical parameters measured were: Probing pocket depth, clinical attachment level and bleeding upon probing. These were evaluated from baseline examination to three months follow-up.

**RESULTS:** The clinical parameters showed improvement in the test group when compared to control group.

**CONCLUSION:** The local delivery of TTO gel in conjunction with conventional periodontal treatment in moderate periodontitis is more effective than SRP therapy alone.

**KEY WORDS:** Clinical attachment level, local drug delivery, moderate periodontitis, scaling and root planning, Tea tree oil gel.

**RUNNING TITLE:** Locally delivered TTO gel in moderate periodontitis

<sup>1</sup> Dentist at Ministry of Health, Alexandria, Egypt.

<sup>2</sup> Professor of Oral Medicine, Periodontology, Oral Diagnosis and Oral Radiology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.

<sup>3</sup> professor of Medical Biochemistry, Faculty of Dentistry, Alexandria University, Alexandria, Egypt.

<sup>4</sup> Associate Professor of Oral Medicine, Periodontology, Oral Diagnosis and Oral Radiology Faculty of Dentistry, Alexandria University, Alexandria, Egypt.

<sup>5</sup> Lecturer of Pharmaceutics. Faculty of Pharmacy, Alexandria University; Alexandria, Egypt.

## \*Corresponding author:

E-mail: [danialabdelaziz@gmail.com](mailto:danialabdelaziz@gmail.com)

## INTRODUCTION

Periodontitis is a chronic inflammation of the periodontium which may lead to loss of the periodontal attachment, increase of the periodontal probing pocket depth, and bone loss. It results from the homeostatic imbalance between the oral microbiota and the host modality to these microorganisms (1).

The proceedings of the World Workshop on the Classification of Periodontal and Peri-implant Diseases and Conditions classified periodontitis into four stages according to the severity and complexity of the treatment. The different stages are initial periodontitis, moderate periodontitis, severe periodontitis with potential for loss of teeth and part of dentition, and severe periodontitis which can lead to total loss of all the dentition. It also includes three grades which depend on the rate of progression and predicted treatment response. Grade A indicates slow progression, grade B moderate progression, and grade C rapid progression (2).

Accurate diagnosis can assess the severity and level of activity of periodontitis leading to the correct

treatment plan. There are several diagnostic procedures such as periodontal probing pocket depth, assessment of mobility, bleeding upon probing, plaque index and using radiographs to assess alveolar bone level (3).

The important role of periodontal management is to prevent disease progression and to overcome and resolve inflammation (4). Mechanical debridement is the first approach, but many studies have proved that mechanical debridement alone cannot eliminate most of the causative micro-organisms and it is related to high recurrence rate (4,5).

The systemic use of antibiotics to treat moderate periodontitis, to prevent or kill periodontal pathogens can be used as an adjunct to conventional therapy of SRP (6).

However, side effects of systemic antibiotics such as toxicity, resistance, sensitivity, growth of opportunistic infection, and interaction with other medications were recorded (5). Therefore, the use of antimicrobials locally may provide a good solution to overcome those complications (7).

Locally delivered drugs result in high drug levels in the periodontal pocket, which can reach the periodontal

tissues as well. This dual effect on pocket micro flora may provide 100-fold higher therapeutic doses of the agent in sub gingival areas than systemic therapy. It also results in enhancement of clinical parameters without systemic side effects (8).

Many pharmaceuticals used today are from natural products (9). Herbal medicines are tested for their effects on periodontitis, in addition to their antibacterial, anti-inflammatory effects and their ability to regenerate periodontal tissue (10,11).

Tea tree oil (TTO) is a herbal drug that has antimicrobial, anti-inflammatory, antifungal, antiviral, and antioxidant effects (12-15). Studies showed useful effects of local delivery of this product in the management of periodontal diseases (11,16,17).

The most important active components of TTO are 1,8-cineole and terpinen-4-ol. These components are common herbal essential oils similar to eucalyptus and fennel oil. 1,8-cineole has anti-inflammatory properties (16,18), and is able to penetrate human skin (19). Terpinen-4-ol has the same properties of 1,8-cineol as an anti-bacterial and anti-inflammatory (14,20-24).

Administration of TTO demonstrated the same antimicrobial properties as chlorhexidine (CHX), with different mechanisms of action. It also has the same antibacterial, antiviral and antifungal properties (21,24-27).

The current study was done to assess the effect of local application of TTO gel as an adjunctive treatment in the management of moderate periodontitis.

The null hypothesis of this research is that there is no superior benefit of topical application of TTO gel in management of moderate periodontitis in non-surgical treatment of periodontal pockets.

## MATERIALS AND METHODS

### Study overview (design)

The current study is a randomized clinical trial conducted according to the CONSORT guidelines (28). (Figure 1)

It was performed on thirty patients, classified into two groups (test and control groups) with moderate periodontitis. The first group (control group) comprised fifteen patients treated with SRP only and the second group (test group) comprised fifteen patients treated with SRP and local delivered TTO gel.

All patients were diagnosed at the outpatient clinic in the Oral Medicine, Periodontology, Oral Diagnosis and Radiology Department, Faculty of Dentistry, Alexandria University, Egypt. All subjects agreed to participate in the clinical trial and signed a written informed consent. Ethical approval was obtained from the Research Ethics Committee at the Faculty of Dentistry, Alexandria University, Egypt (IRBNO: 00010556- IORG:0008839). Helsinki guidelines (2013) for conduct of clinical trials on humans were also followed (29,30).

Eligibility was determined by conducting periodontal evaluation at baseline screening visits to evaluate disease status, periodontal and medical treatment history. Subjects were diagnosed with moderate periodontitis, if they

presented with periodontal pocket depth between  $\geq 5$  mm and  $\leq 7$  mm and CAL was between 3 and 4 mm). All cases showed bleeding on gentle probing (31).

The patients were not accepted in this study if they suffered from any systemic disease or were under any medications. Smokers, pregnant or lactating women were excluded from the study. Also, patients receiving chemotherapeutics during the past six months were excluded.

### Preparation of the gel

The gel used as a local sub gingival application was prepared by the Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University. The gel was prepared by soaking 1% Carbopol 940 in distilled water for 2 hours. TTO (Sigma Aldrich® Steinheim, Germany) was dissolved in an appropriate amount of propylene glycol mixed with the Carbopol dispersion. Methyl paraben 0.2% was dissolved in preheated water. The mixture was made from water which was then magnetically stirred for 30 minutes. The pH was controlled with 1N NaOH added drop wise with gentle stirring with a spatula until the desired pH value (6.5-7) was reached. The gel was sterilized by autoclaving at 110°C for 20 min.

### Treatment procedure

At baseline examination and at three months follow-up evaluation, measurements of PPD, bleeding upon probing, and CAL were made (32).

Measurements were made at six points in each tooth:

Periodontal pocket depth was read by using a graduated periodontal probe. (Figure 2)

At the disto-buccal line angel, mesio-buccal line angel, mid buccal region, disto-lingual line angel mesio-lingual line angel and mid-lingual region. Scaling and root planing were done using manual and ultrasonic scalers and curettes in both groups (Figure 3).

Coronoplasty was done when required and a proper oral hygiene instructions were given to patients in both groups.

### Application of the gel

After the isolation for the test quadrant, the gel was applied by a bent, blunt-ended needle syringe. The needle was carefully inserted in the periodontal pocket and the gel was injected to fill the selected pocket till the gingival margin and the excess gel was removed then periodontal pack was placed at test sites. (Figure 4)

### Patient instructions

Patients were instructed to follow strict oral hygiene measures during the study period. They were also asked not to use the toothbrush at selected site after TTO gel application for 24 hours and not to chew hard or sticky foods at the gel placement sites.

On the subsequent recall visits, no adverse effects were recorded. No probing was made prior to three months in order not to disrupt healing.

### Statistical method

Data were sent to the computer and analyzed using IBM SPSS software package version 20.0. (Armonk, NY: IBM Corp).

The Kolmogorov-Smirnov test was used to measure distribution and normality. Chi-square test for

categorical variables, to compare between different groups. Fisher's Exact Correction for chi-square when more than 20% of the cells have expected count less than 5. Student t-test for normally distributed quantitative variables, to compare between two studied groups. Mann Whitney test for abnormally distributed quantitative variables, to compare between two studied groups. Friedman test for abnormally distributed quantitative variables, to compare between more than two periods or stages and Post Hoc Test (Dunn's) for pairwise comparisons.




Figure (1): Consort Flow chart



Figure (2): Clinical measurement of probing pocket depth by periodontal graduated probe (mm)



Figure (3): A case of moderate periodontitis before and after scaling and root planing.



Figure (4): Sub gingival local delivery of tea tree oil gel after SRP in a periodontal pocket (mm).

**RESULTS**

**Probing pocket depth (in mm)**

No statistically significant difference was seen among the two groups at both baseline examination and after three months at follow up period (P=0.775, P=0.137)

The mean PPD was reduced during the test period in both groups and showed significant decrease (P<sub>1</sub>=0.002, P<sub>1</sub>=0.016). (Table 1, Figure 5).

**Clinical attachment loss (in mm)**


No statistically significant difference was seen between the two groups at both baseline examination and after three months (P=0.539, P=0.174).

The mean CAL was reduced from baseline examination to three months follow up and the difference was statistically significant (P<sub>1</sub><0.001, P<sub>1</sub>=0.001). (Table 1, Figure 5)

**Bleeding on probing (BOP)**

There was no statistically significant difference between the two groups at baseline examination (p=0.318) but it became statically significant when we followed the candidates at three months follow up. (P=0.005) (Figure 5)

Bleeding on probing was reduced during the test period and showed significant decrease in test group more than control group. (P<sub>1</sub><0.001). (Table 1, Figure 5)



**Figure (5):** Comparison between the two groups based on the different clinical measurements

**Table (1):** Comparison between the two groups according to clinical measurements

|                               |               | T               |                    | C     | Sig.  | of   |
|-------------------------------|---------------|-----------------|--------------------|-------|-------|------|
|                               |               | est<br>(n = 15) | ontrol<br>(n = 15) |       |       |      |
| Probing pockets depth         | Baseline      |                 |                    |       |       |      |
|                               | Mean ±        | 5               | 5.                 |       |       |      |
|                               | SD.           | .4 ± 1.1        | 5 ± 1.1            |       |       | t    |
|                               | Median        | 6               | 6                  | =     | 105.5 | .775 |
|                               | (Min. – Max.) | (3 – 6)         | (3 – 6)            |       |       |      |
|                               | 3 months      |                 |                    |       |       |      |
| Mean ±                        | 3             | 4.              |                    |       |       |      |
| SD.                           | .3 ± 0.6      | 3 ± 1.5         |                    |       | t     |      |
| Median                        | 3             | 4               | =                  | 76.50 | .137  |      |
| (Min. – Max.)                 | (2 – 4)       | (2 – 6)         |                    |       |       |      |
| Zp                            |               | 0               | 0.                 |       |       |      |
|                               |               | .002*           | .016*              |       |       |      |
| Clinical attachment loss (mm) | Baseline      |                 |                    |       |       |      |
|                               | Mean ±        | 3               | 3.                 |       |       |      |
|                               | SD.           | .3 ± 0.5        | 4 ± 0.5            |       |       | t    |
|                               | Median        | 3               | 3                  | =     | 97.50 | .539 |
|                               | (Min. – Max.) | (3 – 4)         | (3 – 4)            |       |       |      |
|                               | 3 months      |                 |                    |       |       |      |
| Mean ±                        | 1             | 1.              |                    |       |       |      |
| SD.                           | .4 ± 0.5      | 7 ± 0.6         |                    |       | t     |      |
| Median                        | 1             | 2               | =                  | 79.50 | .174  |      |
| (Min. – Max.)                 | (1 – 2)       | (1 – 3)         |                    |       |       |      |
| Zp                            |               | <               | 0.                 |       |       |      |
|                               |               | 0.001*          | .001*              |       |       |      |
| Bleeding on probing           | Baseline      |                 |                    |       |       |      |
|                               | Mean ±        | 1               | 2.                 |       |       |      |
|                               | SD.           | .9 ± 0.6        | 1 ± 0.5            |       |       | t    |
|                               | Median        | 2               | 2.                 | =     | 1.016 | .318 |
| (Min. – Max.)                 | (1 – 2.8)     | 2 (1.1 – 2.8)   |                    |       |       |      |

|               |              |               |              |
|---------------|--------------|---------------|--------------|
|               |              | 2.8)          |              |
| 3 months      |              |               |              |
| Mean ±        | 0            | 1.            |              |
| SD.           | .7 ± 0.5     | 3 ± 0.4       | t            |
| Median        | 0            | 1.            | =            |
| (Min. – Max.) | .8 (0 – 1.8) | -2 (0.5 – -2) | 3.083* .005* |
| tp            | 0.001*       | <             | <0           |

**U: Mann Whitney test** **t: Student t-test**  
 p: p value for comparing between the studied groups  
 Zp: p value for **Wilcoxon signed ranks test** for comparing between **before and 3months**  
 tp: p value for **Paired t-test** for comparing between **before and 3months**  
 \*: Statistically significant at p ≤ 0.05

**DISCUSSION**

In the current study, locally delivered TTO gel showed to be an effective agent in the treatment of moderate periodontitis. Patients did not report any complications during the study period except for the bad taste of the tea tree oil which was the only complaint from the patients. All patients received conventional periodontal therapy. The test group received intra pocket application of TTO gel in addition to nonsurgical periodontal therapy.

The current study showed a statistically significant decrease in bleeding upon probing and gingival inflammation, which was maintained through the study period in a test group. All groups should show reduction in BP due to SRP and good maintenance. At three months test group may be due to the anti-inflammatory and antibacterial effect of TTO gel. TTO disrupts the microbial membrane structures by changing their permeability (26).

The TTO gel formulation in the present study is similar to the gel preparation in the study by Elgendy et al. (17), which was performed to assess tea tree oil effect on chronic periodontitis. The gel significantly reduced inflammation and bleeding of the gingiva in people with chronic periodontitis. These results are consistent with our current study.

The TTO gel used in the present study also had sustained release properties.

These results are in line with the study conducted in by Soukoulis and Hirsch (11). In the before mentioned work TTO gel was used two times as a dentifrice per day. Gingival inflammation and bleeding index were reduced in patients with severe gingivitis and in those with moderate periodontitis.

In addition, improvement in gingival inflammation due to the anti-inflammatory activity of TTO has been also reported in other studies (14,20). Furthermore, the anti-inflammatory action of TTO

function is to promote superoxide production by human monocytes (14).

Decrease in PPD and improvement in CAL were especially noted in the test group because of reduction in inflammation due to alteration in the sub gingival bacteria (33). In addition the reduction of local factors by scaling may also enhance a local and systemic host response that would aid in promoting the healing process (34).

However, there was no statistically significant difference in PPD between the test and control group in our results at both baseline examination and after three months follow up ( $P=0.775$ ,  $P=0.137$ ) with respect to which variable. The mean PPD was reduced significantly from baseline examination to three months follow-up in individual groups. The reduction in probing pocket depth could be because of the proper oral hygiene measures after SRP. This is in contrast with the study conducted by Arweiler et al. (35), who demonstrated reduction of plaque formation after using tea tree oil in a mouthwash. They found that PPD in the group treated by TTO gel did not differ significantly from patients treated with SRP only during the study period.

In the current study, the mean PPD and CAL were significantly reduced, but this improvement was recorded as higher in the test group in comparison to the control group at three months follow up. Arweiler et al. (35), and Saxer et al. (36), found that TTO had an effect in reducing the oral micro biota. Furthermore, the component of TTO has lipophilic properties that diffuse through epithelium it is proved the anti-inflammatory effect of TTO (19).

## CONCLUSIONS

The results of the study demonstrate that locally delivered TTO gel provides better therapeutic effects than SRP alone. It also proves the efficacy of TTO as an anti-inflammatory agent, which reduces the pro-inflammatory process and enhances the healing process of periodontal tissues.

### Conflict of Interest

The authors declare that they have no conflict of interest.

### Funding

The authors received no specific funding for this work.

## REFERENCES

- Haffajee AD, Socransky SS, Smith C, Dibart S. Microbial risk indicators for periodontal attachment loss. *J Periodontol Res.* 1991;26:293-6.
- Caton JG, Armitage G, Berglundh T, Chapple ILC, Jepsen S, Kornman KS, et al. A new classification scheme for periodontal and peri-implant diseases and conditions - Introduction and key changes from the 1999 classification. *J Periodontol.* 2018;89:1-8.
- Hernández-Ríos P, Hernández M, Garrido M, Tervahartiala T, Leppilähti JM, Kuula H, et al. Oral fluid matrix metalloproteinase (MMP)-8 as a diagnostic tool in chronic periodontitis. *Metalloproteinases in Medicine.* 2016;3:11-8.
- Greenstein G, Caton J. Periodontal disease activity: A critical assessment. *J Periodontol.* 1990;61:543-52.
- Steinberg D, Friedman M, Soskolne A, Sela MN. A new degradable controlled release device for treatment of periodontal disease: In vitro release study. *J Periodontol.* 1990;61:393-8.
- Greenstein G. Clinical significance of bacterial resistance to tetracyclines in the treatment of periodontal diseases. *J Periodontol.* 1995;66:925-32.
- Hanes PJ, Purvis JP. Local anti-infective therapy: Pharmacological agents. A systematic review. *Ann Periodontol.* 2003;8:79-98.
- Jorgensen MG, Slots J. Responsible use of antimicrobials in periodontics. *J Calif Dent Assoc.* 2000;28:185-93.
- Clark AM. Natural products as a resource for new drugs. *Pharm Res.* 1996;13:1133-44.
- Cao CF, Sun XP. Herbal medicine for periodontal diseases. *Int Dent J.* 1998;48:316-22.
- Soukoulis S, Hirsch R. The effects of a tea tree oil-containing gel on plaque and chronic gingivitis. *Aust Dent J.* 2004;49:78-83.
- Jandourek A, Vaishampayan JK, Vazquez JA. Efficacy of melaleuca oral solution for the treatment of fluconazole refractory oral candidiasis in AIDS patients. *AIDS.* 1998;12:1033-7.
- Kim HJ, Chen F, Wu C, Wang X, Chung HY, Jin Z. Evaluation of antioxidant activity of Australian tea tree (*Melaleuca alternifolia*) oil and its components. *J Agric Food Chem.* 2004;52:2849-54.
- Brand C, Ferrante A, Prager RH, Riley TV, Carson CF, Finlay-Jones JJ, et al. The water-soluble components of the essential oil of *Melaleuca alternifolia* (tea tree oil) suppress the production of superoxide by human monocytes, but not neutrophils, activated in vitro. *Inflamm Res.* 2001;50:213-9.
- Koh KJ, Pearce AL, Marshman G, Finlay-Jones JJ, Hart PH. Tea tree oil reduces histamine-induced skin inflammation. *Br J Dermatol.* 2002;147:1212-7.
- Juergens UR, Stober M, Schmidt-Schilling L, Kleuver T, Vetter H. Antiinflammatory effects of eucalyptol (1,8-cineole) in bronchial asthma: inhibition of arachidonic acid metabolism in human blood monocytes ex vivo. *Eur J Med Res.* 1998;3:407-12.
- Elgendy EA, Ali SA, Zineldeen DH. Effect of local application of tea tree (*Melaleuca alternifolia*) oil gel on long pentraxin level used as an adjunctive treatment of chronic periodontitis: A randomized controlled clinical study. *J Indian Soc Periodontol.* 2013;17:444-48.
- Santos FA, Rao VS. Antiinflammatory and antinociceptive effects of 1,8-cineole a terpenoid oxide present in many plant essential oils. *Phytother Res.* 2000;14:240-4.
- Williams AC, Barry BW. Terpenes and the lipid-protein partitioning theory of skin penetration enhancement. *Pharm Res.* 1991;8:17-24.
- Hart PH, Brand C, Carson CF, Riley TV, Prager RH, Finlay-Jones JJ. Terpinen-4-ol, the main component of the essential oil of *Melaleuca alternifolia* (tea tree oil), suppresses inflammatory mediator production by

- activated human monocytes. *Inflamm Res.* 2000;49:619-26.
21. Carson CF, Riley TV. Antimicrobial activity of the major components of the essential oil of *Melaleuca alternifolia*. *J Appl Bacteriol.* 1995;78:264-9.
  22. Hammer KA, Carson CF, Riley TV. In vitro susceptibility of *Malassezia furfur* to the essential oil of *Melaleuca alternifolia*. *J Med Vet Mycol.* 1997;35:375-7.
  23. Hammer KA, Carson, CF, Riley TV. In-vitro activity of essential oils, in particular *Melaleuca alternifolia* (tea tree) oil and tea tree oil products, against *Candida* spp. *J Antimicrob Chemother.* 1998;42:591-5.
  24. May J, Chan CH, King A, Williams L, French GL. Time-kill studies of tea tree oils on clinical isolates. *J Antimicrob Chemother.* 2000;45:639-43.
  25. Shapiro S, Meier A, Guggenheim B. The antimicrobial activity of essential oils and essential oil components towards oral bacteria. *Oral Microbiol Immunol.* 1994;9:202-8.
  26. Cox SD, Mann CM, Markham J, Bell HC, Gustafson JE, Warmington JR, et al. The mode of antimicrobial action of the essential oil of *Melaleuca alternifolia* (tea tree oil). *J Appl Microbiol.* 2000;88:170-6.
  27. Fine DH, Furgang D, Barnett ML, Drew C, Steinberg L, Charles CH, et al. Effect of an essential oil-containing antiseptic mouthrinse on plaque and salivary *Streptococcus mutans* levels. *J Clin Periodontol.* 2000;27:157-61.
  28. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *Trials.* 2010;11:32.
  29. World Medical A. World medical association declaration of helsinki: Ethical principles for medical research involving human subjects. *JAMA.* 2013;310:2191-4.
  30. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMC Med.* 2010;8:18.
  31. Tonetti MS, Greenwell H, Kornman KS. Staging and grading of periodontitis: Framework and proposal of a new classification and case definition. *J Clin Periodontol.* 2018;45:149-61.
  32. Ainamo J, Bay I. Problems and proposals for recording gingivitis and plaque. *Int Dent J.* 1975;25:229-35.
  33. Llambés F, Silvestre FJ, Hernandez-Mijares A, Guiha R, Caffesse R. Effect of non-surgical periodontal treatment with or without doxycycline on the periodontium of type 1 diabetic patients. *J Clin Periodontol.* 2005;32:915-20.
  34. Offenbacher S. Periodontal diseases: Pathogenesis. *Ann Periodontol.* 1996;1:821-78.
  35. Arweiler NB, Donos N, Netuschil L, Reich E, Sculean A. Clinical and antibacterial effect of tea tree oil – A pilot study. *Clin Oral Investig.* 2000;4:70-3.
  36. Saxer UP, Stäubli A, Szabo SH, Menghini G. Effect of mouthwashing with tea tree oil on plaque and inflammation. *Schweiz Monatsschr Zahnmed.* 2003;113:985-96.